Funding Opportunity for Early-Stage Innovators in Scotland
May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment.
🗓️ Deadline: 8th May
At
Pharmidex, we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development.
Our capabilities include:
TargetExpression
ModeOfActionStudies
TargetEngagement
HitIdentification
ADME and PK profiling
If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme.
🔗
https://lnkd.in/eZ6vVjgN


We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.

The success of your research starts with the right model, at the right time. At Pharmidex, we deliver tailored GA breeding solutions combining expert colony management, flexible study design, and rigorous quality control. Backed by AAALAC-accredited facilities and a strong commitment to the 3Rs, we ensure reliable, study-ready models with full traceability. From breeding strategy and genotyping to scalable capacity and flexible timelines, we act as an extension of your team, helping accelerate your research with confidence. 🔬 The right models. When you need them. 🚀 Flexible. Reliable. Research-focused. Let’s build your next breeding strategy.

Pharmidex is pleased to announce that Ian Knowles and Janette Dalay Robertson , will be attending TARGET TO PATIENT 2026 (T2P26) on Monday 20th – Tuesday 21st April 2026 at the Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK. They look forward to meeting founders, investors and biotech leaders to discuss drug discovery, translational partnerships and life science investment opportunities. Feel free to catch them for a chat!




